KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
Study Summary
The purpose of this study is to characterize the PK of xanomeline and trospium in breast milk and plasma in healthy lactating female participants, following multiple oral administration of KarXT in healthy lactating participants.
Lead SponsorKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Data Retrieved2026-04-11 04:08:14.746822+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.